Cipla Ltd, India's fourth-largest drugmaker by revenue, said third-quarter net profit rose 7 percent on strong domestic sales, but fell short of analysts' estimates.
Net profit attributable to shareholders climbed to Rs 4.01 billion ($62.54 million) in the quarter ended Dec. 31, from Rs 3.
75 billion a year earlier.
That compared with an average estimate of Rs 4.44 billion in profit drawn from 18 analysts polled by Thomson Reuters.
Including a one-off positive impact of Rs 1.07 billion due to recalculation of deferred.